TOMOGRAPHY, December 2016, Volume 2, Issue 4: 276-282
Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey
1Departments of Biostatistics and 2Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania; 3Department of Medicine, George Washington University, Washington, D.C.; 4Institute for Computational and Engineering Sciences, and Departments of Biomedical Engineering and Internal Medicine, The University of Texas at Austin, Austin, Texas; 5Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts; 5Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania; 6Division of Medical Oncology, University of Washington, Seattle, Washington; 7Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California; and 8Department of Radiation Oncology, University of Iowa, Iowa City, Iowa
Patient accrual is essential for the success of oncology clinical trials. Recruitment for trials involving the development of quantitative imaging biomarkers may face different challenges than treatment trials. This study surveyed investigators and study personnel for evaluating accrual performance and perceived barriers to accrual and for soliciting solutions to these accrual challenges that are specific to quantitative imaging-based trials. Responses for 25 prospective studies were received from 12 sites. The median percent annual accrual attained was 94.5% (range, 3%–350%). The most commonly selected barrier to recruitment (n = 11/25, 44%) was that “patients decline participation,” followed by “too few eligible patients” (n = 10/25, 40%). In a forced choice for the single greatest recruitment challenge, “too few eligible patients” was the most common response (n = 8/25, 32%). Quantitative analysis and qualitative responses suggested that interactions among institutional, physician, and patient factors contributed to accrual success and challenges. Multidisciplinary collaboration in trial design and execution is essential to accrual success, with attention paid to ensuring and communicating potential trial benefits to enrolled and future patients.
Supplemental Media 1: Appendix Survey: Clinical studies with Quantitative Imaging Biomarkers
View this media larger in a new window